Media Thread, page-17461

Good to see PD1 Vaxx still in the hunt, I had some research on potential BP which is in hunt for PD1 type therapy few months back, on the back of this clinical trial https://clinicaltrials.gov/study/NCT06692959?term=neo%20polem&rank=1

Feature	LM-299 (LaNova/Merck)	PD1-Vaxx (Imugene)

Type of Therapy

Immunotherapy (Bispecific Antibody)

Immunotherapy (B-cell Vaccine)

Target

PD-1 + VEGF (dual target)

PD-1 only

Mechanism of Action

Blocks PD-1 to enhance immune response + inhibits VEGF to cut off tumor blood supply

Trains B-cells to produce antibodies against PD-1

Goal

Improves immune system attack on cancer and reduces tumor blood supply

Enhances immune system’s natural ability to fight tumors

Cancer Types Targeted

Various solid tumors

Solid tumors, colorectal cancer (in trials)

Company

LaNova Medicines (licensed by Merck)

Imugene (Australia)

Clinical Stage

Early-stage development (acquired by Merck in late 2024)

Clinical trials in progress (Neo-POLEM)